|
CheckMate 8KX: Phase 1/2 multitumor preliminary analyses of a subcutaneous formulation of nivolumab (± rHuPH20). |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Incyte; Lilly; Merck Serono; SERVIER |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; Pierre Fabre; Roche; Servier |
Research Funding - Amgen; Merck Serono |
|
|
No Relationships to Disclose |
|
Christopher G. C. A. Jackson |
Honoraria - Athenex; MSD Oncology |
Research Funding - Athenex (Inst) |
Patents, Royalties, Other Intellectual Property - Patent pending - Oraxol - Athenex. No financial interest. |
Travel, Accommodations, Expenses - Athenex |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - MSD; Novartis |
Speakers' Bureau - Bayer; Bristol-Myers Squibb |
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Celgene; Epizyme; Seagen |
Speakers' Bureau - AstraZeneca; Janssen |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Consulting or Advisory Role - GlaxoSmithKline |
Research Funding - Abbisko (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boston Biomedical (Inst); Calithera Biosciences (Inst); Fujifilm (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); InhibRx (Inst); Merck (Inst); Mersana (Inst); Meryx Pharmaceuticals (Inst); Nektar (Inst); Pfizer (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Rgenix (Inst); Seagen (Inst); Sutro Biopharma (Inst); Takeda (Inst); Xencor (Inst) |
|
|
Consulting or Advisory Role - BMS; Boehringer Ingelheim; Merck Serono; Takeda |
Speakers' Bureau - AstraZeneca; Merck Serono; MSD Oncology; Roche |
Travel, Accommodations, Expenses - AstraZeneca; BMS; MSD Oncology |
|
|
Research Funding - Bristol-Myers Squibb; Novartis; SERVIER |
Expert Testimony - Amgen; Amgen; BioSim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; SERVIER |
Travel, Accommodations, Expenses - Amgen; Merck Sharp & Dohme |